




Fig. 6. Exposure of epitopes by GdnHCl treatment. DLPC-treated or untreated PrP^{Sc} was adsorbed to an ELISA plate, digested with PK, and then treated with the various concentrations of GdnHCl indicated at the bottom of the figure. Average and SD of three independent experiments were plotted. Circles indicate the DLPC-treated PrP^{Sc}, whereas squares indicate DLPC-untreated PrP^{Sc}.

contrast, Fig. 6 shows that treatment with of both PrP^{Sc} preparations to GdnHCl dramatically increased the reactivities to all mAbs. This indicates that the dissociation and denaturation of PrP^{Sc} aggregates resulted in pronounced exposure of epitopes. However, one striking difference in the reactivity of mAbs was observed especially at lower GdnHCl concentration: most of the mAbs displayed a higher reactivity to DLPC-treated PrP^{Sc} than to DLPC-untreated PrP^{Sc} at the lower GdnHCl concentrations. This suggests that DLPC-treated PrP^{Sc} may be more sensitive to denaturant than DLPC-untreated PrP^{Sc}.

PrP^{Sc} aggregates are thought to undergo partial denaturation in 2 M GdnHCl, and are believed to be almost completely denatured in 6 M GdnHCl. In parallel with denaturation of PrP^{Sc}, 2 M GdnHCl treatment does not completely abolish prion infectivity, although >4 M GdnHCl treatment drastically reduces the infectivity (Caughey et al., 1997; Prusiner et al., 1993). Table 3 shows the ratio of OD₄₅₀ (in Fig. 6) at 2 and 6 M GdnHCl for both PrP^{Sc} preparations. In DLPC-untreated PrP^{Sc}, the ratios varied from 0.08 to 0.19, suggesting that less than 20% of the epitope for each mAb was exposed following 2 M

GdnHCl treatment. In contrast, the ratios increased, varying from 0.37 to 0.58, following DLPC treatment, indicating that the reduction of PrP^{Sc} size influences the sensitivity to denaturation. The variation of the ratios may reflect the difference in the denaturation process for the specific epitopes. For example, epitopes for mAbs 118 and 43C5 appeared to be more resistant to denaturation by GdnHCl than other epitopes.

Table 3
Reactivity of mAbs to partially denatured PrP^{Sc}

mAb	DLPC-untreated		DLPC-treated	
	OD ₄₅₀ at 2M/6M GdnHCl	Ratio	OD ₄₅₀ at 2M/6M GdnHCl	Ratio
110	0.084/0.789	0.10	0.529/0.994	0.53
132	0.084/1.074	0.08	0.560/1.235	0.45
118	0.295/1.292	0.19	0.488/1.320	0.37
31C6	0.367/2.031	0.18	1.211/2.085	0.58
32	0.167/0.872	0.19	0.305/0.653	0.47
43C5	0.199/1.332	0.15	0.438/1.123	0.39
147	0.271/1.419	0.19	0.581/1.099	0.53
44B1	0.290/1.628	0.18	0.775/1.492	0.52

Discussion

To generate a diverse panel of mAbs to PrP molecules, we established a variety of hybridomas by using rMoPrP and MoPrP^{Sc} purified from scrapie-affected mice brain as immunogens. According to the extensive epitope analyses using rPrP and pepspot membrane, our mAb panel contained mAbs recognizing at least seven different linear epitopes and three discontinuous epitopes. Five of seven linear epitopes were located within the N-terminal half of the PK-resistant core of PrP^{Sc} (aa 119–127, 137–143, 143–149, 147–151, and 163–169). This region is thought to undergo a major conformational change from random coil or α -helix- to β -sheet-rich structure during the conversion of PrP^C to PrP^{Sc}. Among the antibodies, mAb 132, recognizing the epitope aa 119–127 (AVVGGLGGY), is of particular interest. This region is adjacent to the highly amyloidogenic sequence AVAAAVA (aa 112–119) (Gasset et al., 1992) and the first short β -strand (aa 128–131). Studies have shown that this region plays an important role in the conversion of PrP^C to PrP^{Sc} (Holscher et al., 1998; Muramoto et al., 1996). In addition, this region is highly conserved between mammals and birds, suggesting the importance of this region in PrP^C biology (Wopfner et al., 1999). Thus, mAb 132 will facilitate studies of how this region is involved in the conversion process as well as how PrP^C functions. The epitope for mAb 43C5 (aa 163–169) on PrP^C is of also interest because this region, in conjunction with its C-terminal portion, is thought to be a binding domain for an unidentified factor tentatively named protein X, which is expected to act as a molecular chaperon during the conversion process (Kaneko et al., 1997). mAb 43C5 will also be a good tool for studying how this region is involved in the intermolecular interaction. In addition, the first α -helix on PrP^C may undergo α to β conformational change during the conversion process, although this has not been fully clarified (Zhang et al., 1995). The mAbs in groups IIb, IIc, and IId recognizing the first α -helix and its immediate N-terminal portion will therefore contribute to understanding of structural differences in this region.

Elucidation of the PrP^{Sc} structure is an important problem to understand the identity of prion. Although the model structure of PrP^{Sc} and its aggregates were recently proposed from electron crystallography (Wille et al., 2002), their atomic structures remain to be elucidated. Studies of antibody accessibility will help to clarify PrP^{Sc} structure (Kanyo et al., 1999). Our mAbs did not show intense reactivity to PK-treated PrP^{Sc}, which is associated with prion infectivity, although they strongly react with PrP^{Sc} after denaturation. This suggests none of the epitopes recognized by our mAb panel are accessible by mAbs on PrP^{Sc} aggregates. The epitope at the C-terminus of PrP^{Sc} is reported to be accessible to antibody (Peretz et al., 1997; Williamson et al., 1998). In that study, the authors used DLPC treatment, which can disperse the PrP^{Sc} aggregates

into liposome and reduce particle size of PrP^{Sc} aggregates (Gabizon et al., 1987). Although we confirmed that DLPC treatment could reduce the PrP^{Sc} aggregate size, some mAbs including one recognizing the C-terminus showed a trace of reactivity even when we used DLPC-treated PrP^{Sc}. In contrast, denaturation of DLPC-treated PrP^{Sc} was required to expose the cryptic epitopes. This implies that DLPC treatment might not be sufficient to expose the cryptic epitope(s) on PrP^{Sc}. There are some differences in experimental conditions between our investigations and those of Peretz et al. that could explain the differences in our results. First, they used Sc237 hamster scrapie, while we used the Obihiro strain of mouse-adapted scrapie. Second, preparation of PrP^{Sc} for ELISA also varied. Peretz et al. treated PrP^{Sc} with PK and the resulting PrP^{27–30} was dispersed into liposomes. In contrast, we performed DLPC treatment first after which DLPC-treated PrP^{Sc} was digested with PK to eliminate PK-sensitive PrP, which is expected to possess some exposed epitopes. Third, they used streptavidin-coated plates to immobilize the PrP^{Sc} after biotinylation, while, in this study, we directly adsorbed PrP^{Sc} to the ELISA plate by possible hydrophobic interaction. Finally, the antibodies used in the two studies were different. Although pepspot analysis demonstrated that mAbs 39 and 147 recognize an extreme C-terminal part of PrP, we used purified IgG instead of a smaller single-strand Fab fragment. We do not know the reason for the difference in the mAb reactivity to the C-terminus in our results and those reported by Peretz et al., it is conceivable that these differences in the experimental conditions might influence the results.

Denaturation of PrP^{Sc} aggregates caused the exposure of cryptic epitopes (Serban et al., 1990; Williamson et al., 1996). Here we observed that the sensitivity to denaturant varies between the epitopes. In DLPC-treated PrP^{Sc}, the epitopes for mAb 118 and 43C5 appeared to be more resistant to denaturation as determined by the ratio of OD at 2 to 6 M GdnHCl treatment. This difference implies complexity in the inter- or intramolecular interactions involved in the formation of PrP^{Sc} aggregates. It is of particular interest to examine what kind of inter- or intramolecular interactions determine prion infectivity or if exposure of certain epitopes correlates to prion inactivation. Our data also showed that the DLPC-treated PrP^{Sc} is more sensitive to denaturant than DLPC-untreated PrP^{Sc}, indicating that prion inactivation methods are possibly influenced by the state of PrP^{Sc} aggregation and environment.

The epitopes for mAbs raised against rPrP seemed to be relatively restricted, and 9 of 14 mAbs recognized a discontinuous epitope within aa 155–231, indicating this epitope on rPrP was immunodominant in PrP^{-/-} mice. In contrast, the epitopes for the mAbs raised against PrP^{Sc} broadly spanned the PrP molecules. Furthermore, 13 of 14 hybridomas from mice immunized with rPrP secreted IgG1, although hybridomas secreting IgG2b were predom-

inantly established from mice immunized with PrP^{Sc} (9 of 15). Therefore, the differences in the immunodominant regions and predominant immunoglobulin subtypes suggest that the two PrP preparations elicited different type of immune responses, although the two PrPs share primary structure and we used the same immunization procedure. Although PrP^{Sc}-specific antibodies are thought to be an attractive tool for analyzing properties of PrP^{Sc} as well as establishing new diagnostic methods, only one has been previously reported (Korth et al., 1997). Thus, the unique immune response against the PrP^{Sc} fraction suggests that the use of an infectivity-associated PrP^{Sc} fraction as an immunogen may help to generate PrP^{Sc}-specific antibodies. In addition, it is still possible that certain regions are located on the surface of PrP^{Sc} as either a linear epitope or as a PrP^{Sc}-specific discontinuous epitope. Actually, Paramithiotis et al. very recently reported that three amino acid residues, YYR, possibly located in the second β -strand, is not antibody accessible on PrP^C, although the region is exposed on the surface of PrP^{Sc} (Paramithiotis et al., 2003). Further generation of mAbs, especially those specific to PrP^{Sc}, will be required for determining the surface structure of PrP^{Sc}.

BSE and vCJD are now global concerns. Because therapeutics for prion diseases are not currently available, elimination of prion-contaminated foodstuff and biomedical materials is essential for preventing further spread of the disease. We have found that some of our mAbs possessed higher sensitivity for detecting bovine PrP^{Sc} than some commercial-based anti-PrP mAbs, including 6H4 (data not shown). Further generation of anti-PrP antibodies with higher affinity and avidity will contribute to enhance the sensitivity of PrP^{Sc} detection methods.

Materials and methods

Plasmid construction

The prokaryotic expression vectors pET22b(+) (Novagen) and pRSETB (Invitrogen) were used in these studies. For the construction of expression plasmids based on pET22b(+), cDNA encoding mouse (Mo) PrP codons 23–231 was amplified by PCR with primers MPrP2 and MPrP3, and genomic DNA encoding sheep (Sh) PrP codons 25–234 was amplified with primers SPrP102 and SPrP103. Amplified fragments were cloned into the *EcoRV* site of pBluescript KS(+) (Stratagene) to confirm nucleotide sequences. The cloned fragments were excised by *MscI* and *EcoRI* digestion and ligated into the corresponding sites of pET22b(+).

For the construction of expression plasmids based on pRSETB, cDNA encoding MoPrP codons 23–231 was amplified with primers MPrP5 and MPrP3. To express deletion mutants of MoPrP aa 23–167, 23–214, 89–231, and 155–231, we used primer sets of MPrP5 and MPrP9, MPrP5 and MPrP11, MPrP10 and MPrP3, and MPrP12

and MPrP3, respectively, were used for PCR. Hamster (Ha) PrP cDNA encoding codons 23–231, ShPrP gene encoding codons 25–234, and bovine (Bo) PrP cDNA encoding codons 25–242 were amplified with primer sets of MPrP5 and MPrP9, SPrP101 and SPrP102, and BPrP101 and BPrP103, respectively. Amplified fragments were digested with *Bam*HI and *Eco*RI and cloned into the *Bam*HI and *Eco*RI sites of pRSETB. Nucleotide sequences of the cloned PrP gene fragments were confirmed before their expression. To generate the mutant HaPrP containing a single amino acid substitution at codon 179 (Cys to Ala) or 214 (Cys to Ala), we used the ExSite PCR-based site-directed mutagenesis kit (Stratagene) according to the supplier's instructions. Primer sets of HPrP1 and HPrP2, and HPrP3 and HPrP4 were used to introduce the nucleic acid substitution encoding codons 179 and 214, respectively. Primer sequences were as follows: MPrP2, 5'-AATGGCCA AAAAGCGGCCAAAGCCTGGA-3'; MPrP3, 5'-GAGAATTCAGCTGGATCTTCTCCCGTCGT-3'; MPrP5, 5'-AAGGATCC GAAAAAGCGGCCAAAGCCTGG-3'; MPrP9: 5'-GAGAATTC TACTGATCCACTGGCCTGTAG-3'; MPrP10, 5'-AAGGATCC GGGCCAAGGAGGGGTACCCATAATC-3'; MPrP11, 5'-GAGAATTC AGACGCACATCTGCTCCACCAC-3'; MPrP12, 5'-AAGGATCC GCGCTACCCTAACCAAGTGTACT-3'; SPrP101, 5'-AAGGATCC GAAGAAGCGACCAA AACCTGGCGG-3'; SPrP102, 5'-TTGAATTC AACTTGCCCCCTTTGGTAATAAG-3'; SPrP103, 5'-AATGGCCA AGAAGCGACCAAAACCTGGCGG-3'; BPrP101, 5'-AAGGATCC GAAGAAGCGACCAA AACCTGGAGG-3'; BPrP103, 5'-TTGAATTC AACTTGCCCCCTCGTTGGTAATAAG-3'; HPrP1, 5'-CACGATGCTGTCAACATCACCATCAAG-3'; HPrP2, 5'-CACAAAGTTGTTCTGGTTGTTGTACTG-3'; HPrP3, 5'-AGATGGCTACCACCCAGTATCAGAAGG-3'; HPrP4, 5'-GCTCCACCACGCGCTCCATTATCTTG-3' (underlines indicate restriction sites used for cloning, bold indicates stop codons, and italics indicate nucleotide substitutions for the mutation of Cys to Ala).

Expression and purification of recombinant PrP (rPrP)

The expression plasmids based on pRSETB and pET22b(+) were introduced into *E. coli* BL21(DE3)*LysS* and JM109(DE3), respectively. Protein expression was induced by adding isopropylthio- β -D-galactoside to a final concentration at 0.4 mM. Two to four hours after induction, bacterial cells were collected and inclusion bodies were prepared as described elsewhere (Sambrook et al., 1989). The inclusion bodies from BL21(DE3)*LysS* transformed with pRSETB-based expression plasmids were solubilized with 6 M GdnHCl in 20 mM phosphate buffer (pH 7.8). The rPrP was further purified by Ni²⁺-immobilized metal affinity chromatography (IMAC) using Ni²⁺-charged Che- lating Sepharose Fast flow (Amersham Pharmacia) and a

stepwise elution gradient from pH 4.9 to 4.3 in the presence of 6 M GdnHCl. Inclusion bodies from JM109(DE3) transformed with pET22b(+)-based expression plasmids were solubilized with 8 M Urea and 20 mM Tris–HCl, pH 8.0. Next, the urea concentration was reduced to 6 M, and the mixture was applied to DEAE-Sepharose equilibrated with 6 M Urea and 20 mM Tris–HCl, pH 8.0. The unbound fraction was saved for further purification. The rPrP in the eluate from IMAC and the unbound fraction from DEAE-Sepharose were dialyzed against 10 mM acetate buffer (ranging from pH 4.4 to 3.6). After the dialysis, rPrP containing an intramolecular disulfide bond was purified by reverse-phase HPLC using TSKgel Phenyl-5PW RP (TOSOH) and a 30–50% linear gradient of acetonitrile with 0.05% trifluoroacetic acid. The purified rPrP was lyophilized and dissolved with Mili-Q water at 1 mg/ml and stored at -20°C .

Purification of PrP^{Sc} and formation of detergent-lipid-protein complexes (DLPC)

A mouse-adapted scrapie Obihiro strain (Shinagawa et al., 1985) was used in this study. ICR/Slc female mice were inoculated intracerebrally with 20 μl of brain homogenate of Obihiro strain infected-mice and were sacrificed under anesthesia when they showed the clinical symptoms of the terminal stage of the disease. PrP^{Sc} was purified from the scrapie-affected mice brains without proteinase K treatment as described by Bolton et al. (1987) with minor modifications (Caughey et al., 1991). Protein concentration was determined by DC protein assay kit (Bio-Rad).

Ten micrograms of purified PrP^{Sc} was suspended in 1.6 ml of DLPC buffer containing 2% Sarkosyl, 0.4% phosphatidylcholine, 150 mM NaCl, and 50 mM Tris–HCl, pH 8.3. The suspension was sonicated for five cycles of 2 s with a Branson Sonifier Contamination-free Ultrasonic Sample Pre-processing System.

Production of monoclonal antibodies

Purified PrP^{Sc}, rMoPrP23–231, or rMoPrP89–231 was mixed with an equal volume of Freund's complete adjuvant and 200 μg of each PrP was inoculated subcutaneously into PrP gene-ablated mice (Yokoyama et al., 2001). After the first immunization, the mice received 100 μg of the same PrP preparation with Freund's incomplete adjuvant twice every 2 weeks. The booster shot was given intraperitoneally with 50 μg of each PrP preparation in PBS. Three days after the booster, splenocytes obtained from immunized mice were fused with P3U1 mouse myeloma cells using polyethylene glycol 1500 (Roche Diagnostic) according to the supplier's instruction, and hybridomas were selected in HAT medium. Hybridoma culture supernatants were screened by ELISA using purified PrP^{Sc} and rMoPrP as described below. The hybridomas secreting

mAbs were cloned by limiting dilution. The isotypes of the mAbs were determined using the IsoStrip mouse monoclonal antibody isotyping kit (Roche Diagnostic). Large-scale preparations of mAbs were carried out in INTEGRA CELLline high density culture units (IBS Integra Biosciences). The supernatants harvested from the units were concentrated by precipitation with 50% saturated ammonium sulfate and then purified by size exclusion chromatography with Superdex-200 HR (Amersham Pharmacia Biotech).

ELISA

Ninety-six well plates (MaxiSorp, Nunc) were coated overnight at 4°C with either 200 ng/well of purified PrP^{Sc} or 100 ng/well of rMoPrP in 50 μl of 20 mM phosphate buffer, pH 7.0. After adsorption, wells were blocked with 5% fetal bovine serum (FBS) in PBS containing 0.1% Tween 20 (PBST) for 2 h at room temperature (r.t.), and then incubated with culture supernatants or antibodies diluted with 1% FBS in PBST for 1 h. After washing with PBST, wells were incubated with 100 μl of 1:2500 diluted HRP-conjugated F(ab')₂ fragment anti-mouse Ig (Amersham Bioscience) for 1 h. Finally, antigen–antibody complexes were detected by adding a substrate solution of 100 $\mu\text{g}/\text{ml}$ of 2,2'-azino-bis(3-ethyl-benzthiazoline-6-sulfonic acid), 0.04% H₂O₂ in 50 mM citrate-phosphate buffer, pH 4.0, and the absorbance at 405 nm was measured with a microplate reader (Multiscan MS-UV, Labsystems). A ready to use 3,3',5,5'-tetramethylbenzidine (TMB) was also used as a substrate, and the absorbance at 450 nm was measured for TMB.

Immunoblotting

The preparation of PrP^{Sc} and immunoblotting were carried out as described elsewhere (Grathwohl et al., 1997). The blots were developed with ECL Western blotting detection reagents (Amersham Pharmacia) and immunoreactive proteins were detected with X-ray film.

Pepspots analysis

In these studies, we used pepspots membrane to which an array of 99 overlapping synthetic peptides, corresponding to residues 23–231 of mouse PrP, was covalently attached to a cellulose support via carboxyl termini. Each peptide is 13 amino acid residues long, and there is a two amino acid shift along the mouse PrP amino acid sequence from one peptide to the next. The membrane was blocked with 5% skim milk and 5% sucrose in PBST, and then incubated with culture supernatants of hybridomas as primary antibodies. Bound antibodies were detected using a 1:2500 diluted HRP-conjugated F(ab')₂ fragment anti-mouse Ig and an ECL Western blotting detection reagent.

Acknowledgments

This work was supported by a grant from The 21st Century COE Program (A-1), and a Grant-in-Aid for Science Research (A) (grant 15208029) and (B) (grant 12460130) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan. This work was also supported by a grant from the Ministry of Health, Labour and Welfare of Japan.

References

- Barry, R.A., Prusiner, S.B., 1986. Monoclonal antibodies to the cellular and scrapie prion proteins. *J. Infect. Dis.* 154, 518–521.
- Bolton, D.C., Bendheim, P.E., Marmorstein, A.D., Potempska, A., 1987. Isolation and structural studies of the intact scrapie agent protein. *Arch. Biochem. Biophys.* 258, 579–590.
- Caughey, B.W., Dong, A., Bhat, K.S., Ernst, D., Hayes, S.F., Caughey, W.S., 1991. Secondary structure analysis of the scrapie-associated protein PrP 27–30 in water by infrared spectroscopy. *Biochemistry* 30, 7672–7680.
- Caughey, B., Kocisko, D.A., Raymond, G.J., Lansbury Jr., P.T., 1995. Aggregates of scrapie-associated prion protein induce the cell-free conversion of protease-sensitive prion protein to the protease-resistant state. *Chem. Biol.* 2, 807–817.
- Caughey, B., Raymond, G.J., Kocisko, D.A., Lansbury Jr., P.T., 1997. Scrapie infectivity correlates with converting activity, protease resistance, and aggregation of scrapie-associated prion protein in guanidine denaturation studies. *J. Virol.* 71, 4107–4110.
- Gabizon, R., McKinley, M.P., Prusiner, S.B., 1987. Purified prion proteins and scrapie infectivity copartition into liposomes. *Proc. Natl. Acad. Sci. U.S.A.* 84, 4017–4021.
- Gasset, M., Baldwin, M.A., Lloyd, D.H., Gabriel, J.M., Holtzman, D.M., Cohen, F., Fletterick, R., Prusiner, S.B., 1992. Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid. *Proc. Natl. Acad. Sci. U.S.A.* 89, 10940–10944.
- Grathwohl, K.U., Horiuchi, M., Ishiguro, N., Shinagawa, M., 1997. Sensitive enzyme-linked immunosorbent assay for detection of PrP(Sc) in crude tissue extracts from scrapie-affected mice. *J. Virol. Methods* 64, 205–216.
- Harmeyer, S., Pfaff, E., Groschup, M.H., 1998. Synthetic peptide vaccines yield monoclonal antibodies to cellular and pathological prion proteins of ruminants. *J. Gen. Virol.* 79, 937–945.
- Holscher, C., Delius, H., Burkle, A., 1998. Overexpression of nonconvertible PrP delta114–121 in scrapie-infected mouse neuroblastoma cells leads to trans-dominant inhibition of wild-type PrP(Sc) accumulation. *J. Virol.* 72, 1153–1159.
- Hope, J., Morton, L.J., Farquhar, C.F., Multhaup, G., Beyreuther, K., Kimberlin, R.H., 1986. The major polypeptide of scrapie-associated fibrils (SAF) has the same size, charge distribution and N-terminal protein sequence as predicted for the normal brain protein (PrP). *EMBO J.* 5, 2591–2597.
- Horiuchi, M., Yamazaki, N., Ikeda, T., Ishiguro, N., Shinagawa, M., 1995. A cellular form of prion protein (PrP^C) exists in many non-neuronal tissues of sheep. *J. Gen. Virol.* 76, 2583–2587.
- Kaneko, K., Zulianello, L., Scott, M., Cooper, C.M., Wallace, A.C., James, T.L., Cohen, F.E., Prusiner, S.B., 1997. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. *Proc. Natl. Acad. Sci. U.S.A.* 94, 10069–10074.
- Kanyo, Z.F., Pan, K.M., Williamson, R.A., Burton, D.R., Prusiner, S.B., Fletterick, R.J., Cohen, F.E., 1999. Antibody binding defines a structure for an epitope that participates in the PrP^C → PrP^{Sc} conformational change. *J. Mol. Biol.* 293, 855–863.
- Kascsak, R.J., Rubenstein, R., Merz, P.A., Tonna-DeMasi, M., Fersko, R., Carp, R.I., Wisniewski, H.M., Diringer, H., 1987. Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. *J. Virol.* 61, 3688–3693.
- Korth, C., Stierli, B., Streit, P., Moser, M., Schaller, O., Fischer, R., Schulz-Schaeffer, W., Kretzschmar, H., Raeber, A., Braun, U., Ehrensperger, F., Hornemann, S., Glockshuber, R., Riek, R., Billeter, M., Wuthrich, K., Oesch, B., 1997. Prion (PrP^{Sc})-specific epitope defined by a monoclonal antibody. *Nature* 390, 74–77.
- Krasemann, S., Groschup, M.H., Harmeyer, S., Hunsmann, G., Bodemer, W., 1996. Generation of monoclonal antibodies against human prion proteins in PrP0/0 mice. *Mol. Med.* 2, 725–734.
- Meyer, R.K., McKinley, M.P., Bowman, K.A., Braunfeld, M.B., Barry, R.A., Prusiner, S.B., 1986. Separation and properties of cellular and scrapie prion proteins. *Proc. Natl. Acad. Sci. U.S.A.* 83, 2310–2314.
- Muramoto, T., Scott, M., Cohen, F.E., Prusiner, S.B., 1996. Recombinant scrapie-like prion protein of 106 amino acids is soluble. *Proc. Natl. Acad. Sci. U.S.A.* 93, 15457–15462.
- O'Rourke, K.I., Baszler, T.V., Miller, J.M., Spraker, T.R., Sadler-Rigglesman, I., Knowles, D.P., 1998. Monoclonal antibody F89/160.1.5 defines a conserved epitope on the ruminant prion protein. *J. Clin. Microbiol.* 36, 1750–1755.
- Pan, K.M., Baldwin, M., Nguyen, J., Gasset, M., Serban, A., Groth, D., Mehlhorn, I., Huang, Z., Fletterick, R.J., Cohen, F.E., 1993. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. *Proc. Natl. Acad. Sci. U.S.A.* 90, 10962–10966.
- Paramithiotis, E., Pinard, M., Lawton, T., LaBoissiere, S., Leathers, V.L., Zou, W.Q., Estey, L.A., Lamontagne, J., Lehto, M.T., Kondejewski, L.H., Francoeur, G.P., Papadopoulos, M., Haghighat, A., Spatz, S.J., Head, M., Will, R., Ironside, J., O'Rourke, K., Tonelli, Q., Ledebur, H.C., Chakrabarty, A., Cashman, N.R., 2003. A prion protein epitope selective for the pathologically misfolded conformation. *Nat. Med.* 9, 893–899.
- Peretz, D., Williamson, R.A., Matsunaga, Y., Serban, H., Pinilla, C., Bastidas, R.B., Rozenshteyn, R., James, T.L., Houghten, R.A., Cohen, F.E., Prusiner, S.B., Burton, D.R., 1997. A conformational transition at the N terminus of the prion protein features in formation of the scrapie isoform. *J. Mol. Biol.* 273, 614–622.
- Prusiner, S.B., 1991. Molecular biology of prion diseases. *Science* 252, 1515–1522.
- Prusiner, S.B., Groth, D., Serban, A., Stahl, N., Gabizon, R., 1993. Attempts to restore scrapie prion infectivity after exposure to protein denaturants. *Proc. Natl. Acad. Sci. U.S.A.* 90, 2793–2797.
- Riek, R., Hornemann, S., Wider, G., Billeter, M., Glockshuber, R., Wuthrich, K., 1996. NMR structure of the mouse prion protein domain PrP(121–321). *Nature* 382, 180–182.
- Safar, J., Roller, P.P., Gajdusek, D.C., Gibbs Jr., C.J., 1993. Conformational transitions, dissociation, and unfolding of scrapie amyloid (prion) protein. *J. Biol. Chem.* 268, 20276–20284.
- Sambrook, J., Fritsch, E.F., Maniatis, T., 1989. *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Press, Cold Spring Harbor, NY.
- Serban, D., Taraboulos, A., DeArmond, S.J., Prusiner, S.B., 1990. Rapid detection of Creutzfeldt–Jakob disease and scrapie prion proteins. *Neurology* 40, 110–117.
- Shinagawa, M., Takahashi, K., Sasaki, S., Doi, S., Goto, H., Sato, G., 1985. Characterization of scrapie agent isolated from sheep in Japan. *Microbiol. Immunol.* 29, 543–551.
- Wille, H., Michelitsch, M.D., Guenebaut, V., Supattapone, S., Serban, A., Cohen, F.E., Agard, D.A., Prusiner, S.B., 2002. Structural studies of the scrapie prion protein by electron crystallography. *Proc. Natl. Acad. Sci. U.S.A.* 99, 3563–3568.
- Williamson, R.A., Peretz, D., Smorodinsky, N., Bastidas, R., Serban, H., Mehlhorn, I., DeArmond, S.J., Prusiner, S.B., Burton, D.R., 1996. Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein. *Proc. Natl. Acad. Sci. U.S.A.* 93, 7279–7282.
- Williamson, R.A., Peretz, D., Pinilla, C., Ball, H., Bastidas, R.B., Rozenshteyn, R., Houghten, R.A., Prusiner, S.B., Burton, D.R., 1998. Mapping the prion protein using recombinant antibodies. *J. Virol.* 72, 9413–9418.
- Wopfner, F., Weidenhofer, G., Schneider, R., von Brunn, A., Gilch, S.,

- Schwarz, T.F., Werner, T., Schatzl, H.M., 1999. Analysis of 27 mammalian and 9 avian PrPs reveals high conservation of flexible regions of the prion protein. *J. Mol. Biol.* 289, 1163–1178.
- Yokoyama, T., Kimura, K.M., Ushiki, Y., Yamada, S., Morooka, A., Nakashiba, T., Sassa, T., Itohara, S., 2001. In vivo conversion of cellular prion protein to pathogenic isoforms, as monitored by conformation-specific antibodies. *J. Biol. Chem.* 276, 11265–11271.
- Zanusso, G., Liu, D., Ferrari, S., Hegyi, I., Yin, X., Aguzzi, A., Hornemann, S., Liemann, S., Glockshuber, R., Manson, J.C., Brown, P., Petersen, R.B., Gambetti, P., Sy, M.S., 1998. Prion protein expression in different species: analysis with a panel of new mAbs. *Proc. Natl. Acad. Sci. U.S.A.* 95, 8812–8816.
- Zhang, H., Kaneko, K., Nguyen, J.T., Livshits, T.L., Baldwin, M.A., Cohen, F.E., James, T.L., Prusiner, S.B., 1995. Conformational transitions in peptides containing two putative alpha-helices of the prion protein. *J. Mol. Biol.* 250, 514–526.